BMC Medicine, 2020 Background Beta-blockers are widely used for many cardiovascular conditions; however, their efficacy in contemporary clinical practice remains uncertain.
O. Ziff +6 more
semanticscholar +1 more source
Molecules, 2022 Beta-blockers are antihypertensive drugs and can be abused by athletes in some sport competitions; it is therefore necessary to monitor beta-blocker levels in biological samples.
Aliya Nur Hasanah +2 more
doaj +1 more source
Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. [PDF]
, 2007 BACKGROUND: It is unclear whether beta-blocker therapy should be reduced or withdrawn in patients who develop acute decompensated heart failure (HF). We studied the relationship between changes in beta-blocker dose and outcome in patients surviving a
A, +18 more
core +1 more source
Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. [PDF]
, 2005 AIMS: We studied the influence of heart rate (HR), systolic blood pressure (SBP), and beta-blocker dose on outcome in the 2599 out of 3029 patients in Carvedilol Or Metoprolol European Trial (COMET) who were alive and on study drug at 4 months after ...
Charlesworth A +11 more
core +1 more source
Association Between Lipophilic Beta-Blockers and Depression in Diabetic Patients on Chronic Dialysis
Clinical Medicine Insights: Endocrinology and Diabetes, 2022 Background: Depression is associated with lower quality of life and increased risk of mortality. The prevalence of depression in chronic dialysis patients, as well as in patients with diabetes, is more than 20%. It is debated whether use of beta-blockers
Robin Lengton +6 more
doaj +1 more source
Effects of sacubitril/valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy [PDF]
, 2016 Background—In the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan was more effective than the ...
Gong, Jianjian +11 more
core +2 more sources
Jurnal Kedokteran Diponegoro, 2017 Latar Belakang : Penurunan sensibilitas kornea merupakan salah satu efek samping dari penggunaan beta blocker topikal yang dapat menimbulkan berbagai masalah seperti penurunan reflex mengedip, penurunan kemampuan penyembuhan luka pada kornea, dan terkait
Tusita Devi, Fifin Luthfia Rahmi
doaj +1 more source
Tailoring therapy for heart failure: the pharmacogenomics of adrenergic receptor signaling. [PDF]
, 2014 Heart failure is one of the leading causes of mortality in Western countries, and β-blockers are a cornerstone of its treatment. However, the response to these drugs is variable among individuals, which might be explained, at least in part, by genetic ...
Barrese, V +3 more
core +2 more sources
Case of chronic indolent pheochromocytoma that caused medically controlled hypertension but treatment-resistant diabetes mellitus [PDF]
, 2017 No abstract ...
Cho, Eun Joo +4 more
core +1 more source
Cardiovascular Ultrasound, 2010 Background Upright exercise stress echocardiography (SE) induces significant intraventricular gradient (IVG) and systolic anterior motion (SAM) in a large proportion of symptomatic athletes, who may therefore benefit from a negative inotropic therapy ...
Cotrim Carlos +8 more
doaj +1 more source